Free tool
FAERS Monitor: Forteo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021318 or its brand name (Forteo, Teriparatide). Reports on generic versions are filed under their own applications.
Reports
112,496
Serious
41,897
37% of reports
Hospitalization
24,294
Death reported
5,314
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea9,026
- arthralgia8,725
- pain in extremity8,375
- dizziness8,337
- fall7,933
- pain7,575
- fatigue7,225
- back pain5,948
- muscle spasms5,753
- malaise5,689
- headache5,528
- asthenia5,454
- injection site erythema5,069
- injection site pain4,845
- injection site bruising4,794
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 6,414 |
| 2005 | 4,792 |
| 2006 | 2,193 |
| 2007 | 2,193 |
| 2008 | 2,133 |
| 2009 | 3,068 |
| 2010 | 3,799 |
| 2011 | 5,405 |
| 2012 | 6,250 |
| 2013 | 2,648 |
| 2014 | 1,297 |
| 2015 | 44,975 |
| 2016 | 2,140 |
| 2017 | 4,040 |
| 2018 | 4,898 |
| 2019 | 4,011 |
| 2020 | 1,957 |
| 2021 | 1,813 |
| 2022 | 1,581 |
| 2023 | 1,757 |
| 2024 | 1,839 |
| 2025 | 2,090 |
| 2026 | 1,203 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,941,663 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| injection site bruisingSignal | 4,794 | 11.9 | 11.6 | 45,102 |
| injection site erythemaSignal | 5,069 | 7.9 | 7.7 | 29,578 |
| muscle spasmsSignal | 5,753 | 6.0 | 5.9 | 23,519 |
| pain in extremitySignal | 8,375 | 5.4 | 5.3 | 29,905 |
| back painSignal | 5,948 | 4.9 | 4.8 | 18,110 |
| fallSignal | 7,933 | 4.5 | 4.4 | 21,722 |
| arthralgiaSignal | 8,725 | 4.0 | 3.9 | 19,490 |
| dizzinessSignal | 8,337 | 3.2 | 3.1 | 12,405 |
| injection site painSignal | 4,845 | 3.0 | 2.9 | 6,383 |
| astheniaSignal | 5,454 | 2.7 | 2.7 | 6,032 |
| malaiseSignal | 5,689 | 2.4 | 2.4 | 4,891 |
| painSignal | 7,575 | 2.3 | 2.3 | 5,798 |
| nauseaSignal | 9,026 | 2.1 | 2.1 | 5,668 |
| fatigue | 7,225 | 1.7 | 1.7 | 2,348 |
| headache | 5,528 | 1.7 | 1.6 | 1,461 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.